Drug Profile

NIO 752

Alternative Names: NIO-752

Latest Information Update: 06 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis Pharmaceuticals
Class Antisense oligonucleotides
Mechanism of Action Gene silencing; RNA interference; Tau protein expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

17 Oct 2024 Novartis Pharmaceuticals completes the phase I trial in Progressive supranuclear palsy (In adults, In elderly)in Canada, Germany, United Kingdom, USA (Intrathecal) (NCT04539041)
13 May 2024 Phase-I development is ongoing in Progressive-supranuclear-palsy in United Kingdom, USA, Canada and Germany (NCT04539041)
23 Apr 2024 University of College, London plans a phase I trial for Alzheimer's disease (Intrathecal) in May 2024 (NCT06372821)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com